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high doses of olanzapine on appetite/ metabolic regulatory signals in the hypothalamus and brainstem to 
elucidate the mechanisms underlying olanzapineinduced obesity. Methodology/Results: Levels of pro-
opiomelanocortin (POMC), neuropeptide Y (NPY) and glutamic acid decarboxylase (GAD65, enzyme for 
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Abstract
Background/Aim: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic
side-effects, such as obesity and diabetes. This study examined the effects of low to high doses of olanzapine on appetite/
metabolic regulatory signals in the hypothalamus and brainstem to elucidate the mechanisms underlying olanzapine-
induced obesity.
Methodology/Results: Levels of pro-opiomelanocortin (POMC), neuropeptide Y (NPY) and glutamic acid decarboxylase
(GAD65, enzyme for GABA synthesis) mRNA expression, and cannabinoid CB1 receptor (CB1R) binding density (using [
3H]SR-
141716A) were examined in the arcuate nucleus (Arc) and dorsal vagal complex (DVC) of female Sprague Dawley rats
following 0.25, 0.5, 1.0 or 2.0 mg/kg olanzapine or vehicle (36/day, 14-days). Consistent with its weight gain liability,
olanzapine significantly decreased anorexigenic POMC and increased orexigenic NPY mRNA expression in a dose-sensitive
manner in the Arc. GAD65 mRNA expression increased and CB1R binding density decreased in the Arc and DVC. Alterations
to neurotransmission signals in the brain significantly correlated with body weight and adiposity. The minimum dosage
threshold required to induce weight gain in the rat was 0.5 mg/kg olanzapine.
Conclusions: Olanzapine-induced weight gain is associated with reduced appetite-inhibiting POMC and increased NPY. This
study also supports a role for the CB1R and GABA in the mechanisms underlying weight gain side-effects, possibly by
altering POMC transmission. Metabolic dysfunction can be modelled in the female rat using low, clinically-comparable
olanzapine doses when administered in-line with the half-life of the drug.
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Introduction
The second generation antipsychotic (SGA) olanzapine is
prescribed to treat schizophrenia and a growing number of other
disorders in adults and children [1–8], but can cause adverse
metabolic side-effects including increased body weight [9], caloric
intake [10,11] and abdominal adiposity [12,13], and reduced
physical activity [14–16]. Metabolic side-effects are a growing
concern due to co-morbidities such as diabetes and obesity [17],
and are a risk factor for medication non-compliance [18]. A
number of potential mechanisms for SGA-induced metabolic
dysfunction have emerged over the past few years [19–21]. In
particular, the histaminergic, serotonergic and dopaminergic
neurotransmitter systems are thought to be highly implicated in
SGA-induced body weight gain [21–26]. However, SGAs have a
broad receptor binding profile that allows direct and indirect
effects on multiple neural and peripheral signalling pathways
[26], and further research into other candidate systems is
required.
The hypothalamic arcuate nucleus (Arc) and the dorsal vagal
complex (DVC) of the brainstem are well-documented for their
role in appetite and energy homeostasis [27–29]; responding to the
acute nutritional status and long-term regulation of energy stores
in the body. Neurons of the Arc and DVC express Gi/o-coupled
cannabinoid CB1 receptors (CB1R) [30,31], which facilitate the
effects of cannabinoids on appetite and energy metabolism [32].
Weight gain during olanzapine and clozapine treatment is
associated with a CB1R gene polymorphism in individuals with
chronic schizophrenia [33], and chronic high-dose risperidone
treatment increases cannabinoid receptor agonist, [3H]CP-55940,
binding density in the Arc of male rats [34]. We previously
demonstrated a decrease in [3H]CP-55940 binding density in the
DVC of rats treated with olanzapine, but not aripiprazole or
haloperidol [35]. However, whether changes in receptor density
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were attributed to the CB1R is unclear due to the low specificity of
the ligand used [36] and localisation of cannabinoid CB2 receptors
in the brain [37]. Moreover, the effects of olanzapine on CB1R
density in the Arc remain unknown.
The appetite enhancing effects of the major neuronal inhibitor,
c-aminobutyric acid (GABA) in the hypothalamus were reported
more than 30 years ago [38]. GABAergic neurons in the Arc are
sensitive to leptin [39], and GABA receptor agonists and
antagonists stimulate and suppress feeding behaviour, respectively
[40]. Down-regulated expression of glutamic acid decarboxylase
(GAD, the GABA synthesising enzyme) has been observed in
individuals with schizophrenia, bipolar and mood disorder,
whereas antipsychotic drug treatment increases cortical GAD
expression in rats and primates [41]. GAD exists as two isoforms,
65 and 67; the latter is found throughout the neuronal cytoplasm,
whereas GAD65 is located primarily in the axon terminal [42–44]
and is the predominant transcript in the hypothalamus of the adult
rat brain [45]. However, to our knowledge the effects of
olanzapine on GAD65 mRNA expression in the hypothalamic
Arc or the DVC have not been investigated.
The Arc and DVC both express mRNA for orexigenic
neuropeptide Y (NPY) and anorexigenic pro-opiomelanocortin
(POMC) [46–48]. The POMC gene encodes for neuropeptides
such as adrenocorticotropic hormone, b-endorphin and a-
melanocortin stimulating hormone; the latter of which exerts its
anorexigenic effects largely through melanocortin-3 and melano-
cortin-4 receptor (MC4-R) subtypes [49]. Conversely, the central
application of NPY induces food intake in a number of species
[50], hypolocomotor activity in rats [51,52], and can lead to
obesity following chronic over-exposure [53,54]. Therefore, it is
possible that interference in the balance of POMC and NPY by
olanzapine may contribute to the drug’s obesogenic liability.
Several reports demonstrated increased NPY immunoreactivity in
the Arc of clozapine-treated rats [55,56], whereas chronic
risperidone treatment in male rats had no effect on POMC or
NPY expression, or body weight [34], which may be due to the
lower sensitivity of male rats to SGA-induced metabolic side-
effects compared to females [57–60]. Other studies have examined
antipsychotic effects on NPY mRNA expression in the brain with
region-dependent outcomes [61–65]. The effects of antipsychotics
on POMC or NPY in the brainstem have not been examined and
studies on hypothalamic appetite-regulating peptides during
olanzapine treatment are confounding; one group reported an
increase in orexigenic NPY and AgRP and a concurrent reduction
in appetite-inhibiting POMC and cocaine- and amphetamine-
related transcript (CART) [66], whilst another reported no change
in several hypothalamic peptides, including NPY and POMC [67].
A key factor that may contribute to the difference in findings is
drug dosage (i.e.: 1 mg/kg olanzapine [66] vs. a supratherapeutic
dose of 3 mg/kg olanzapine [67] (b.i.d.). Indeed, metabolic
outcomes can differ with antipsychotic dosage [68–71] and
increased dose induces greater metabolic dysfunction in the rat
[66,72,73], however, high antipsychotic dosages in the rat may not
represent the clinic [74]. In addition, both studies had a large
dosage interval, i.e.: 6–7 then 17–18 hourly treatments, b.i.d.
[66,67]. As the half-life of olanzapine is 5.1 hours in the rat brain
with high levels remaining after 8-hours [75], compared to
approximately 75.2 hours in the human brain [76], multiple
dosages are required in the rat in order to minimise drug
fluctuations below sub-therapeutic D2 receptor occupancy levels
[74,77]. Therefore, it may be possible to model olanzapine-
induced metabolic dysfunction in the rat using low olanzapine
dosages when administered in accordance with the half-life of the
drug, i.e.: 8 hourly (t.i.d.) within in 24-hours.
Using an established rat model of olanzapine-induced metabolic
dysfunction [35,70,78–80], this study aimed to investigate the
mechanisms underlying weight gain associated with olanzapine
treatment by examining its effects on POMC, NPY and GAD65
mRNA expression, and CB1R binding density (using the CB1R-
specific ligand [3H]-SR141716A) in the Arc and DVC. Statistical
correlations between these parameters in the brain and body
weight, food intake and visceral adiposity were investigated. To
identify the minimum dosage threshold required to induce
metabolic change, rats were treated with different clinically-
relevant olanzapine dosages, calculated based on comparable
therapeutic in-vivo dopamine D2 receptor occupancy levels [74]
and differences in body surface area between species [81].
Collectively, the present study demonstrates that olanzapine
changes the balance of anorexigenic POMC and orexigenic
NPY mRNA expression in the Arc, does not alter POMC or NPY
in the DVC, and increases GAD65 mRNA expression but reduces
CB1R density in both the hypothalamus and brainstem. These
largely dose-sensitive changes may underlie a shift in energy
balance that favours weight gain during olanzapine treatment.
Metabolic dysfunction can be modelled in the female rat using low
olanzapine doses when administered in-line with the half-life of the
drug.
Methods
Ethics Statement
All experimental procedures were approved by the Animal
Ethics Committee (Approval #: AE06/32), University of Wollon-
gong, and complied with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (2004). All efforts
were made to minimise animal distress and prevent suffering.
Animals and Treatment
Seven week-old female Sprague Dawley rats (Animal Resources
Centre, Perth, WA, Australia), housed in 12-h light–dark cycle
(lights on 07:00, 22uC) were habituated for 1-week, then randomly
assigned to 0.25, 0.5, 1.0 or 2.0 mg olanzapine/kg (Zyprexa, Eli
Lilly, Indianapolis, IN, USA) or vehicle (control) (n = 12),
administered three-times daily in a sweet cookie dough pellet, as
described previously [70]. Briefly, olanzapine tablets were de-
coated and pulverized then the assigned dosage was added to
measured dry ingredients. Water droplets were added immediately
prior to administration to achieve a dry-dough consistency. After a
1-week teaching period, rats learnt to voluntarily self-administer a
0.3 g cookie-dough pellet either containing the assigned dosage of
olanzapine, or plain cookie-dough without the drug (control
group), offered by a metal spoon at 8-hourly intervals (3 pellets/
day) for 14-days. Consumption of each pellet was observed to
ensure complete dosing. Body weight and food intake measure-
ments were recorded (n = 12). Animals were allowed ad libitum
access to water and standard laboratory chow diet throughout the
study. Animals were fasted for 4–6 hours then euthanized using
sodium pentobarbitone 10–12 hours after the last treatment. Brain
tissue was immediately frozen in liquid nitrogen and stored at
280uC. Visceral (perirenal and periovary) white fat pads were
dissected and weighed (n = 12). Six brains were randomly selected
from each treatment group for use in the mRNA expression and
receptor binding experiments. Tissue was sectioned (14 mm,
218uC) along the coronal plane then stored at 220uC.
NPY, POMC and GAD65 mRNA In-Situ Hybridisation
POMC mRNA expression was observed using in-situ hybrid-
isation techniques previously described by our laboratory [82],
Effects of Olanzapine on Neural Metabolic Signals
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using the following specific antisense hybridisation probe: 59-
CGTTCTTGATGATGGCGTTCTTGAAGAGCGTCACCAG-
GGGCGTCT-39 (J00612, 547–591). NPY mRNA expression was
observed using in-situ hybridisation techniques previously de-
scribed by our laboratory [65,82], using the following specific
antisense hybridisation probe: 59-GAGTGTATCTGGCCATG-
TCCTCTGCTGGCGCGTCCTCGCCCGG-39 (M15792, 1650–
1693). GAD65 mRNA expression was observed using the following
specific antisense hybridisation probe: 59-GGCGTCCACACTG-
CAAGGCCTTGTCTCCCGTGTCATAGGACAGGTCAT-39
(NM_012563.1, 1419-1372), as previously described by Ling et al.,
[83]. Oligonucleotide probes were terminally labelled using
[35S]dATP (1000 Ci/mmol, Perkin Elmer, Waltham, MA, USA)
in 10-fold molar excess and terminal transferase (Promega,
Madison, WI, USA), then purified using a MicroSpin G-50
column (GE Healthcare Ltd, Buckinghamshire, UK). Hybridisa-
tion was performed by incubating slides in hybridisation buffer (46
SSC, 16 Denhardt’s solution, 50% de-ionised formamide,
200 mg/ml sperm DNA, 100 mg/1 ml polyA, 120 mg/ml heparin,
20 mM sodium phosphate and labelled probe, pH 7.0) for 18-
hours at 37uC. Slides were then washed in 16SSC buffer at 55uC
(3630-minutes each) and incubated for 1-hour in SSC buffer at
room temperature. Sections were dipped in Milli-Q water followed
sequentially by 70% then 95% ethanol, and dried under a gentle
stream of air. Autoradiographic images were captured on film
(Kodak BioMax MR film, Rochester, NY, USA) exposed for 3-
weeks. Films were quantified using a GS-800 Densitometer (Bio-
Rad Laboratories, Inc), and analysis software (Quantity One,
v4.6.7, Bio-Rad Laboratories, Inc, CA, USA). Values were derived
from a standard curve generated from a [14C]-labelled autora-
diographic standard (GE Healthcare Ltd, Buckinghamshire, UK)
(mean binding nCi/g tissue equivalent vs. density). Slides were
dipped in Emulsion solution (GE Healthcare Ltd, Buckingham-
shire, UK) and exposed for 6-weeks, then stained with cresyl violet
(Nissl stain) (Sigma-Aldrich, NSW, Australia), to allow further
examination of positive signals at the cellular level.
CB1R Binding Density
CB1R binding density was detected using methods previously
published by our laboratory [84]. Briefly, air-dried slides were pre-
incubated for 15 min in incubation buffer containing 50 mM
Tris–HCl buffer (pH 7.4) and 0.1% bovine serum albumin, at
room temperature. Sections were then incubated with 10 nM [3H]
SR141716A (52 Ci/mMol, Amersham, UK), a CB1R-specific
inverse agonist, in buffer (pH 7.4) at room temperature for
60 minutes to determine total binding. Non-specific binding was
determined by incubating subsequent sections in 10 nM [3H]
SR141716A in the presence of 100 mM CP-55940, in buffer
(pH 7.4) for 60 minutes at room temperature. Slides were washed
in ice cold buffer (pH 7.4), (2630 minutes), then dipped in distilled
water and dried under a gentle stream of cool air. CB1R
autoradiographic images were captured using a Beta Image
camera (BioSpace, Paris, France), which counts the amount of b-
particles emitted from the tissue (3.5 hours exposure) to determine
the level of radioactivity bound to the brain sections. Radioactive
levels were obtained in counts per minute per square millimetre of
tissue (cpm/mm2), converted to nCi/mg tissue equivalent using
standard tissue sections calibrated with commercial standards
(Amersham, Buckinghamshire, United Kingdom), then trans-
formed into fmol/mg tissue equivalent by taking into account the
specific activity of the radioligand (52 Ci/mMol). Quantification
was conducted using b-Image Plus software (version 4, BioSpace,
Paris, France).
Quantification and Statistical Analysis
Quantification of autoradiographic images was performed on
the hypothalamic Arc and the DVC of the brainstem, which were
confirmed using a corresponding set of cresyl violet-stained slides
and a standard rat brain atlas [85]. Data were analysed using
SPSS (version 17.0, SPSS, Chicago, IL, USA). All data points were
within 62 standard deviations. One-Sample Kolmogorov-Smir-
nov tests revealed normal data distribution. One-way ANOVAs
were employed to determine the effect of treatment on percentage
body weight change, food intake, visceral adiposity, as well as
NPY, POMC and GAD65 mRNA expression, and CB1R binding
density in the hypothalamus and brainstem. ANOVAs were
followed by multiple comparisons using post-hoc Dunnett-T tests
where relevant (p,0.05). Correlations were identified using
Pearson’s correlation tests.
Results
Body Weight, Food Intake and Visceral Adiposity
There was a significant effect of treatment on the percentage of
body weight change from treatment day 0 (F4,55 = 7.68, p,0.01).
Compared to controls, olanzapine significantly increased percent-
age of body weight change in the 0.5 mg/kg (p,0.05), 1.0 mg/kg
and 2.0 mg/kg (p,0.01) treatment groups, but not in the low
dosage group of 0.25 mg/kg (p.0.05) (Figure 1A). Mean
cumulative food intake significantly increased in the 2.0 mg/kg
Figure 1. Weight Gain and Visceral Adiposity. (A): Percentage body weight change and (B): visceral adiposity in female Sprague Dawley rats
(n = 12/treatment group) treated with 0.25, 0.5, 1.0 or 2.0 mg/kg olanzapine or vehicle (control), (14-days, t.i.d). Data expressed as mean6SEM.
*p,0.05, **p,0.01 vs. control.
doi:10.1371/journal.pone.0033548.g001
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olanzapine dosage group compared to the control group
(318.6611.2 g vs. 269.4611.1 g, p,0.05). An increase (7–8%) in
food intake was also observed in the 0.5 mg/kg and 1.0 mg/kg
olanzapine treatment groups, but did not reach significance
compared to the controls (0.5 mg/kg: 289.1613.9 g vs. 269.46
11.1 g, 1.0 mg/kg: 291.6612.1 g vs. 269.4611.1 g, p.0.05), and
the low dosage group (0.25 mg/kg) did not differ to the control
group (265.4611.7 g vs. 269.4611.1 g). Olanzapine treatment
had a significant effect on visceral adiposity (F4,55 = 4.60, p,0.01),
with a significant increase observed in the 2.0 mg/kg olanzapine
treatment group (p,0.05) and a trend for an increase in the
1.0 mg/kg dosage group (p = 0.09), but not in the lower dosage
groups (p.0.05) (Figure 1B).
POMC and NPY mRNA Expression
Examples of POMC and NPY mRNA expression in the
hypothalamus are shown in Figure 2A–D. Olanzapine had a
significant effect on POMC mRNA expression in the Arc
(F4,25 = 8.32, p,0.01), not in the DVC (F4,25 = 1.44, p = 0.25)
(Figure 3A). Post-hoc analysis identified a significant decrease in
POMC mRNA expression in the Arc following dosages of
0.5 mg/kg, 1.0 mg/kg and 2.0 mg/kg (p,0.01) olanzapine, but
not 0.25 mg/kg olanzapine (p = 0.90), compared to controls
(Figure 3A). There was also a significant effect of treatment on
NPY mRNA expression in the Arc (F4,25 = 8.55, p,0.01), with a
significant increase in the Arc following 1.0 mg/kg and 2.0 mg/kg
olanzapine (Figure 3B), but not in the lower dosage groups
(p = 0.34 and p = 0.11 for 0.25 mg/kg and 0.5 mg/kg olanzapine,
respectively) (Figure 3B). NPY mRNA expression in the DVC was
unaltered by olanzapine (F4,25 = 0.73, p = 0.58) (Figure 3B).
GAD65 mRNA Expression
Examples of GAD65 mRNA expression are shown in Figure 2E–
F. A significant effect of treatment on GAD65 mRNA expression
was observed in the Arc (F4,25 = 5.21, p,0.01) and DVC
(F4,25 = 7.73, p,0.01), with an increase following olanzapine
dosages of 1.0 mg/kg (Arc p,0.05, DVC p,0.01) and 2.0 mg/
kg (both regions p,0.01), but not in the 0.5 mg/kg or 0.25 mg/kg
groups (p.0.05), compared to controls (Figure 3C).
CB1R Binding Density
An example of CB1R binding density in the hypothalamus and
DVC is shown in Figure 4. There was a significant effect of
treatment on CB1R binding density in the Arc (F4,25 = 7.48,
p,0.01), with a reduction in all olanzapine treatment groups
compared to controls (p,0.01) (Figure 3D). Olanzapine decreased
CB1R binding density in the DVC (F4,25 = 3.48, p,0.05) of
animals treated with 0.5 mg/kg, 1.0 mg/kg or 2.0 mg/kg
olanzapine (p,0.05), but not 0.25 mg/kg olanzapine (p = 0.43)
(Figure 3D).
Correlations
POMC mRNA expression in the Arc significantly correlated to
percentage body weight change (r = 20.43, p,0.05), visceral
adiposity (r = 20.49, p,0.01), NPY mRNA expression (r = 20.45,
p,0.05), and GAD65 mRNA expression in the Arc (r = 20.54,
p,0.01) (Figure 5A–D). There was a significant positive
correlation between NPY and GAD65 mRNA expression in the
Arc (r = 0.69, p,0.01) (Figure 5E), however the two factors did not
correlate to percentage body weight change (p.0.05). CB1R
binding density in the DVC correlated to percentage body weight
change (r = 20.38, p,0.05), visceral adiposity (r = 20.38, p,0.05)
and GAD65 mRNA expression in the DVC (r = 20.52, p,0.01)
(Figure 5F–H), and a weak correlation was observed between
CB1R binding density in the Arc and percentage body weight
change (r = 20.33, p = 0.08).
Discussion
We found that olanzapine alters signals in the hypothalamus
and brainstem that are implicated in appetite and energy
Figure 2. Examples of POMC, NPY and GAD65 mRNA Expres-
sion Following Olanzapine Treatment. Examples of pro-opiome-
lanocortin (POMC), neuropeptide Y (NPY) and glutamic acid decarbox-
ylase 65 (GAD65) mRNA expression in the female Sprague Dawley rat
brain following 2.0 mg/kg olanzapine treatment (A-A9, C-C9, E-E9) or
vehicle (control) (B-B9, D-D9, F-F9) for 14-days (t.i.d.). (A–F): Low
magnification film autoradiographs depicting mRNA expression in the
rat brain, (A9–F9): High magnification emulsion/cresyl violet–stained
slides showing mRNA expression specifically in the arcuate nucleus.
Autoradiographs are examples of raw data used for the graphs
depicted in Figure 3A–C and are average representations of 6 rats per
treatment group.
doi:10.1371/journal.pone.0033548.g002
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homeostasis in a largely dose-sensitive manner. These changes
may underlie a shift in energy balance that favours weight gain.
The data support a role for POMC in the mechanisms underlying
olanzapine-induced obesity. Reduced POMC satiety signalling
leads to obesity in the clinic and in animal models of obesity, for
example, POMC mRNA expression is attenuated in genetically
obese Zucker rats [86], tubby mice (tub gene mutation) [87] and
diet-induced obese mice [88]. In addition, genetic POMC
deficiency leads to obesity in humans [89] and mice [90], and
MC4-R deficiency leads to morbid obesity associated with
enhanced adiposity and chronic hyperphagia [91]. The result of
unaltered POMC mRNA expression in the DVC was not entirely
surprising as the role of POMC neurons in the DVC is not well-
characterised, and functional and chemical distinctions to the Arc
have been identified [92,93].
NPY mRNA expression was upregulated in the Arc following
1.0 mg/kg and 2.0 mg/kg olanzapine treatment, however no
significant correlation with weight gain was observed. This is
consistent with some NPY transgenic and deficiency models i.e.:
mice and rats that over-express NPY do not have a hyperphagic/
obese phenotype [94], and genetic modelling of NPY-deficiency
does not result in reduced body weight, adiposity, or food intake
[95–97]. However, it is possible that NPY had an indirect effect on
weight gain in olanzapine-treated animals, for example by
inhibiting POMC. Indeed, NPY neurons synapse on POMC cell
bodies and can inhibit their spontaneous activity [98–100],
however, unlike POMC, NPY mRNA expression did not change
in the 0.5 mg/kg olanzapine treatment group suggesting a role for
other systems in POMC regulation. The dosage response of NPY
mRNA expression was in-line with the increase in GAD65 mRNA
expression in the 1.0 mg/kg and 2.0 mg/kg olanzapine treatment
groups, although GAD65 mRNA expression increased in both the
Figure 3. Dosage Effects of Olanzapine Treatment on POMC, NPY and GAD65 mRNA Expression, and CB1R Binding Density. (A): Pro-
opiomelanocortin mRNA expression (nCi/g tissue), (B): neuropeptide Y mRNA expression (nCi/g tissue), (C): glutamic acid decarboxylase (GAD65)
mRNA expression (nCi/g tissue), (D): cannabinoid CB1 receptor binding density (fmoles/mg tissue), in rats treated with 0.25. 0.5, 1.0 or 2.0 mg/kg
olanzapine or vehicle (control) (14-days, t.i.d.) (n = 6/treatment group). Key: & arcuate nucleus % dorsal vagal complex. Data is expressed as mean 6
SEM. *p,0.05, **p,0.01 vs. control.
doi:10.1371/journal.pone.0033548.g003
Figure 4. Example of CB1R Binding Density Following Olanza-
pine Treatment. Example of cannabinoid CB1 receptor binding
density (using [3H]SR-141716A) in the A, C: hypothalamic arcuate
nucleus and B, D: dorsal vagal complex of the caudal brainstem of
female Sprague Dawley rats following A, B: 2.0 mg/kg olanzapine
treatment, C, D: vehicle (control) for 14-days (t.i.d.). Autoradiographs
are examples of raw data used for the graphs depicted in Figure 3D and
are average representations of 6 rats per treatment group.
doi:10.1371/journal.pone.0033548.g004
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Arc and DVC. Upregulated GABAergic signalling during weight
gain is consistent with previous reports that whilst NPY and/or
AgRP gene deficiency is insufficient to reduce food intake [101],
ablation of NPY/AgRP/GABA neurons results in acute hypo-
phagia [102] and deletion of vesicular GABA transporter in AgRP
neurons (which co-express NPY) results in a lean, obesity-resistant
phenotype in mice [103]. GABA is co-localised in approximately
30% of POMC [104] and NPY/AgRP neurons in the Arc [105],
and GABA derived from NPY/GABA axons can suppress
spontaneous firing of POMC neurons [98]. In addition, a dense
population of leptin-responsive, largely non-AgRP GABAergic
neurons that increase inhibitory post-synaptic currents in POMC
neurons were recently identified in the Arc [39]. Therefore, the
increase in Arc GAD mRNA expression observed in the present
study may have arisen from a number of GABAergic sources.
Olanzapine treatment elicited a robust reduction in CB1R
density in the Arc and DVC. Using the CB1R-specific ligand,
[3H]-SR141716A, we confirm that our original findings of a
reduction in [3H]CP-55940 binding density in the DVC during
olanzapine treatment [35] were attributed to the CB1R sub-type
and extend these findings into the hypothalamus. CB1R number
and cell signal transduction pathways decrease following over-
exposure to agonists [106] and animal models of obesity, for
example obese db/db and ob/ob mice, and fatty Zucker rats, exhibit
elevated hypothalamic endocannabinoid levels [107]. Therefore,
reduced CB1R binding density following olanzapine treatment
may be a result of increased endogenous cannabinoids. Endog-
enous cannabinoids play an important regulatory role in synaptic
transmission by modulating neuronal excitatory and inhibitory
input [108,109]. Interestingly, POMC neurons secrete endocan-
nabinoids under basal conditions that retrogradely activate CB1Rs
expressed on GABAergic neurons [110,111]. G-protein sub-units
coupled to the CB1R inhibit the opening of calcium channels,
which reduces vesicular release of GABA [109]. CB1R activation
can relieve inhibitory input to the post-synaptic POMC neuron
[110–112]. We suggest that reduced CB1R density during
olanzapine treatment may diminish cannabinoid-regulated inhi-
bition of GABA, and therefore enhance GABAergic input to
POMC neurons, suppressing POMC and encouraging body
weight gain (Figure 6). In addition, anandamide and CP-55940
increase NPY release in the hypothalamus [113], therefore,
increased endocannabinoid levels may contribute to an increase
in NPY during olanzapine treatment that further suppresses
POMC (Figure 6). CB1Rs can also modulate GABA and
glutamate release in the DVC [30], however the functional
implications of changes in CB1R density and GAD65 mRNA
expression during olanzapine treatment require further investiga-
tion. Additionally, the influence of olanzapine on other neuro-
transmitter systems may play a role in the mechanisms underlying
SGA-induced weight gain [25,114]. For example, olanzapine is a
potent histamine H1 receptor antagonist [115] and antipsychotic
affinity for the H1 receptor can predict its weight gain liability
[114], however the underlying mechanisms for the effect of the H1
receptor on antipsychotic-induced body weight may be indepen-
dent of melanocortinergic neurotransmission [116]. On the other
hand, dopamine D1 and D2 receptor antagonism influences
hypothalamic NPY mRNA expression [117–119] and serotonin 5-
HT2C receptor agonists can activate POMC neurons [120,121],
therefore, the antagonistic affinity of olanzapine to D2 and 5-
HT2C receptors [122,123] may contribute to its weight gain side-
effects [24]. These receptors may form broader components of the
mechanism proposed in the present study, however further
research is necessary.
Our finding of a decrease in POMC and increase in NPY
mRNA expression during olanzapine treatment coincide with
Ferno et al [66], but contrast to the lack of change reported by
Davoodi et al [67]. As discussed earlier, these studies differ in
olanzapine dosage and treatment interval [66,67]. Additionally, in
Davoodi’s study animals were not fasted and PCR methods were
used to detect expressional changes in the whole hypothalamus
[67], whereas rats were fasted prior to euthanasia and in-situ
hybridisation techniques were utilised to target expression
specifically in the Arc in the present study and [66]. Furthermore,
patterns of daily changes in hypothalamic NPY and POMC gene
expression have been reported [124], therefore timing of
euthanasia may also confound results. A previous study from our
laboratory reported a drug withdrawal response of NPY mRNA
expression to olanzapine treatment cessation, i.e.: no change in
Arc NPY mRNA expression after 2-hour drug washout and a
decrease after 48-hour withdrawal after 5-weeks olanzapine
treatment [65]. As body weight associated with olanzapine
treatment follows a ‘peak-and-plateau’ trend over time
[71,79,125], the lack of change in NPY mRNA expression [65]
may be related to compensatory mechanisms that coincide with a
plateau in body weight. Further investigation into the time-
dependent pattern of NPY mRNA expression during chronic
olanzapine treatment would be useful.
Secher et al. [34] reported increased [3H]CP-55940 binding
density in the Arc following 28-days risperidone treatment, and
observed a significant correlation between plasma drug levels and
visceral adiposity. These results are similar to our study as
olanzapine influenced CB1R density in the Arc and changes in
CB1R density correlated with adiposity. Differences in the
direction of CB1R density change may be attributed to several
differences in experimental design in Secher et al.’s study [34],
including drug dosage above the upper clinical limit [34],
administration method i.e.: continuous drug application via
mini-pump with no drug washout period, and treatment duration
as time-dependent changes in CB1R density and transduction
pathways have been reported [106]. Neither drugs have an affinity
for the CB1R (.10,000 Ki (nM) [126,127]), indicating that effects
on the CB1R are secondary changes and exactly how these SGAs
influence CB1Rs should be investigated in future studies. An
olanzapine-induced decrease in CB1R binding density seems
contrary to the orexigenic influence of CB1R activation, and
appetite suppression of CB1R blockade [128]. However, there is
vast potential for the endogenous cannabinoid system to modulate
metabolism, including central and peripheral effects on food intake
and reward aspects of feeding, glucose and lipid metabolism, and
energy expenditure [129–136]; aspects of which may contribute to
the weight loss efficacy of rimonabant [135]. Olanzapine-induced
weight gain is associated with increased GABA and decreased
Figure 5. Correlations. Correlations between pro-opiomelanocortin (POMC) mRNA expression in the arcuate (Arc) nucleus and (A): percentage of
body weight change, (B): visceral adipose tissue, (C): neuropeptide Y (NPY) mRNA expression in the Arc, (D): glutamic acid decarboxylase (GAD65)
mRNA expression in the Arc, (E): Arc NPY and GAD65 mRNA expression, (F): cannabinoid CB1 receptor (CB1R) binding density in the dorsal vagal
complex (DVC) and percentage of body weight changed, (G): DVC CB1R binding density and visceral adipose tissue, and (H): DVC CB1R binding
density and GAD65 mRNA expression, following 14-days olanzapine treatment or vehicle (control). Correlation analyses were made from raw data
underlying the graphs presented in Figures 1 and 3. Key: control, 60.5 mg/kg, # 0.5 mg/kg, % 1.0 mg/kg, n 2.0 mg/kg olanzapine.
doi:10.1371/journal.pone.0033548.g005
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Figure 6. A Proposed Mechanism for Olanzapine-Induced Weight Gain through Interactions Between POMC, NPY, CB1 and GABA
systems. (A) Normal Conditions. Schematic illustrating proposed inhibitory synaptic transmission to the POMC neuron modulated by NPY,
cannabinoid and GABAergic systems under normal conditions. (1) Endogenous cannabinoids are released from the post-synaptic POMC neuron and
retrogradely activate CB1 receptors located on the non-AgRP GABAergic neuron (2). GABA is synthesised from glutamate via the rate limiting enzyme
GAD (3), however G-protein sub-units coupled to the CB1R inhibit the opening of calcium channels (4), which reduces vesicular release of GABA from
the presynaptic terminal to the POMC neuron (5), disinhibiting POMC (6). A number of NPY neurons co-express GABA and can also inhibit POMC.
These NPY/AgRP/GABA neurons synapse on POMC neurons and can regulate POMC cell activity (7). (B) Olanzapine Treatment: Our data
demonstrates that olanzapine decreases POMC mRNA expression and CB1R binding density, whilst simultaneously increasing NPY and GAD mRNA
expression. Based on these findings we suggest a potential mechanism contributing to weight gain during olanzapine treatment. (1) Increased GAD
mRNA expression enhances the potential for GABA production, whilst (2) decreased CB1R density following olanzapine treatment may remove
inhibition of calcium channels (3) and allow vesicular release of GABA (4). The combined effect may be to increase GABA production and release. (5)
Olanzapine increases NPY mRNA expression, which can inhibit POMC activation (6). Therefore, reduced CB1R density, and enhanced GAD and NPY
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CB1R density, whereas anorexigenic rimonabant, decreases
GABA release from NPY/AgRP/GABA neurons, possibly via
modulation of cannabinoid-sensitive opioid peptides [112]. This
suggests that although olanzapine and rimonabant influence the
CB1R, they exert their effects through different modes of action.
The doses used in the present study were selected based on the
recommended clinical olanzapine dosage range of 5–20 mg/day
[70,74,81] excluding the 0.25 mg/kg treatment group, which was
included as a minimum response threshold. Olanzapine was
administered every 8-hours, based on the half-life of olanzapine in
the rat brain [75], to minimise inappropriate peaks and troughs in
drug levels between treatments [74]. The present study demon-
strates that olanzapine-induced metabolic dysfunction can be
modelled in the female rat using low olanzapine dosages when
treatment is administered in accordance with the half-life of the
drug. In addition, treatment was voluntarily self-administered
orally in a cookie-dough pellet, which aimed to minimise potential
handling stress [137] and maintain a consistently high drug dosage
in the brain [74,75]. Oral drug administration in rats requires a
teaching period to ensure voluntary pellet consumption, however
this method resembles clinical administration and may circumvent
limitations reported using other administration techniques, such as
mini-pump, injection and gavage [74,138–140]. Consistent with
the clinic [141], olanzapine has a sedative effect in the rat at high
doses [72] and we previously reported a general trend of reduced
locomotor activity in response to increasing olanzapine dosage
[70]. It is possible that sedation plays a role in weight gain during
olanzapine treatment, however, as hyperphagia was only apparent
in the high dosage group (2 mg/kg olanzapine) in the present
study, it is unlikely that sedation influenced the animal’s ability to
consume food.
In conclusion, our data demonstrates that olanzapine, an
antipsychotic drug with a high metabolic liability, alters key
metabolic signals in the hypothalamus and brainstem in a manner
that favours positive energy balance and may contribute to its
weight gain/obesity side-effects. Olanzapine decreases anorexi-
genic POMC, increases orexigenic NPY, and alters CB1R and
GABAergic signalling in a largely dose-sensitive manner. Low
dosages of 0.5 mg/kg and 1.0 mg/kg olanzapine (t.i.d.) were
sufficient to induce metabolic changes. Drug dosage may
contribute, in-part, to inconsistencies observed between reports
in the literature. Enhanced body weight and visceral adiposity
during olanzapine treatment are associated with reduced anorex-
igenic POMC mRNA expression. We propose that increased NPY
and enhanced inhibitory GABAergic input, possibly through
reduced CB1R density, may contribute to POMC inhibition
(Figure 6). However, the present study has several limitations,
firstly, statistical correlations do not provide direct evidence of a
causal link, and secondly, changes to mRNA and receptor binding
density may not reflect a functional protein change, therefore
further studies are required to confirm the mechanism proposed in
the present study. Examination of olanzapine’s effects on the
GAD67 isoform and other hypothalamic neuropeptides, such as
AgRP and CART, would be useful, as well as investigation into
the time-response of all parameters at different intervals during
treatment. Finally, as CB1R density decreased in all olanzapine
dosage groups, experiments using lower dosages are required to
identify the minimum dosage threshold. Taken together, this study
supports a role for the melanocortinergic, GABAergic and
cannabinoid systems in the underlying mechanisms contributing
to olanzapine-induced weight gain side-effects and provides
direction on dosage consideration for future animal modelling
studies.
Acknowledgments
We sincerely thank Dr Kai Kang, Dr Mei Han, Ms Kelly Liu and Ms
Jiamei Lian for their expert technical assistance.
Author Contributions
Conceived and designed the experiments: KWG XH CD. Performed the
experiments: KWG. Analyzed the data: KWG XH CD. Contributed
reagents/materials/analysis tools: KWG XH CD. Wrote the paper: KWG
XH CD.
References
1. Ballard C, Waite J, Birks J (2006) Atypical antipsychotics for aggression and
psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews
2006: Art. No.: CD003476. DOI: 003410.001002/14651858.CD14003476.
pub14651852.
2. Brambilla F, Monteleone P, Maj M (2007) Olanzapine-induced weight gain in
anorexia nervosa: Involvement of leptin and ghrelin secretion? Psychoneur-
oendocrinology 32: 402–406.
3. Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, et al. (2004) A rapid and
systematic review and economic evaluation of the clinical and cost-effectiveness
of newer drugs for treatment of mania associated with bipolar affective
disorder. Health Technol Assess 8: iii–iv.
4. Budman C, Gayer A, Lesser M, Shi Q, Bruun R (2001) An open-label study of
the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry
62: 290–294.
5. Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, et al. (2002)
Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989. Am J Psychiatry
159: 1932–1935.
6. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011)
Metabolic and endocrine adverse effects of second-generation antipsychotics in
children and adolescents: A systematic review of randomized, placebo
controlled trials and guidelines for clinical practice. Eur Psychiat 26: 144–158.
7. Frenchman IB (2005) Atypical antipsychotics for nursing home patients: a
retrospective chart review. Drugs & Aging 22: 257–264.
8. Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of Schizophrenic
Patients: Preponderance of Off-Label Drug Use. PLoS ONE 3: e3150.
9. Newcomer J (2005) Second-Generation Atypical Antipsychotics and Metabolic
Effects. A Comprehensive Literature Review. CNS Drugs 19: 1–93.
10. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, et al. (2001)
Association of olanzapine-induced weight gain with an increase in body fat.
Am J Psych 158: 1719.
11. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, et al. (2002) Weight Gain
Associated With Increased Food Intake and Low Habitual Activity Levels in
Male Adolescent Schizophrenic Inpatients Treated With Olanzapine.
Am J Psychiatry 159: 1055–1057.
12. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The
effects of atypical antipsychotics on visceral fat distribution in first episode,
drug-naive patients with schizophrenia. Life Sci 74: 1999–2008.
13. Zhang Z-J, Yao Z-J, Liu WEN, Fang QUN, Reynolds GP (2004) Effects of
antipsychotics on fat deposition and changes in leptin and insulin levels:
Magnetic resonance imaging study of previously untreated people with
schizophrenia. Br J Psychiatry 184: 58–62.
14. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, et al.
(2009) Obesity Among Those with Mental Disorders: A National Institute of
Mental Health Meeting Report. Am J Prev Med 36: 341–350.
15. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of
people with schizophrenia. Psychol Med 29: 697–701.
16. Archie S, Wilson J, Osborne S, Hobbs H, McNiven J (2003) Pilot study: access
to fitness facility and exercise levels in olanzapine-treated patients.
Can J Psychiatry 48: 628–632.
17. Rader DJ (2007) Effect of Insulin Resistance, Dyslipidemia, and Intra-
abdominal Adiposity on the Development of Cardiovascular Disease and
Diabetes Mellitus. Am J Med 120: S12–S18.
18. Weiden PJ, Mackell JA, McDonnell DD (2004) Obesity as a risk factor for
antipsychotic noncompliance. Schizophr Res 66: 51–57.
may contribute to the suppression of POMC (7). As POMC is an important anorexigenic peptide, its prolonged inhibition during olanzapine treatment
may lead to increased body weight and adiposity side-effects.
doi:10.1371/journal.pone.0033548.g006
Effects of Olanzapine on Neural Metabolic Signals
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33548
19. Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-
induced metabolic derangement: Clues for understanding obesity and novel
drug design. Pharmacol Ther 127: 210–251.
20. Starrenburg FCJ, Bogers JPAM (2009) How can antipsychotics cause diabetes
mellitus? Insights based on receptor-binding profiles, humoral factors and
transporter proteins. Eur Psychiat 24: 164–170.
21. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug
treatment - pharmacological mechanisms. Pharmacol Ther 125: 169–179.
22. Deng C, Weston-Green K, Huang X-F (2010) The role of histaminergic H1
and H3 receptors in food intake: A mechanism for atypical antipsychotic-
induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 34: 1–4.
23. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007)
Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-
linked activation of hypothalamic AMP-kinase. Proceedings of the National
Academy of Sciences 104: 3456–3459.
24. Kirk S, Glazebrook J, Grayson B, Neill J, Reynolds G (2009) Olanzapine-
induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.
Psychopharmacology 207: 119–125.
25. Matsui-Sakata A, Ohtani H, Sawada Y (2005) Receptor occupancy-based
analysis of the contributions of various receptors to antipsychotics-induced
weight gain and diabetes mellitus. Drug Metabolism and Pharmacokinetics 20:
368–378.
26. Nasrallah H (2008) Atypical antipsychotic-induced metabolic side effects:
insights from receptor-binding profiles. Mol Psychiat 13: 27–35.
27. Berthoud H-R (2002) Multiple neural systems controlling food intake and body
weight. Neurosci Biobehav Rev 26: 393–428.
28. Broberger C, Hökfelt T (2001) Hypothalamic and vagal neuropeptide
circuitries regulating food intake. Physiol Behav 74: 669–682.
29. Faulconbridge LF, Grill HJ, Kaplan JM, Daniels D (2008) Caudal brainstem
delivery of ghrelin induces fos expression in the nucleus of the solitary tract, but
not in the arcuate or paraventricular nuclei of the hypothalamus. Brain Res
1218: 151–157.
30. Derbenev AV, Stuart TC, Smith BN (2004) Cannabinoids suppress synaptic
input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol
(Lond) 559: 923–938.
31. Berrendero F, Romero J, Garcı́a-Gil L, Suarez I, De la Cruz P, et al. (1998)
Changes in cannabinoid receptor binding and mRNA levels in several brain
regions of aged rats. Biochimica et Biophysica Acta (BBA) - Molecular Basis of
Disease 1407: 205–214.
32. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F
(2010) The endocannabinoid system, eating behavior and energy homeostasis:
The end or a new beginning? Pharmacol Biochem Behav 95: 375–382.
33. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, et al. (2010) A Common
Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with
Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharma-
cology 35: 1315–1324.
34. Secher A, Husum H, Holst B, Egerod KL, Mellerup E (2010) Risperidone
Treatment Increases CB1 Receptor Binding in Rat Brain. Neuroendocrinology
91: 155.
35. Weston-Green K, Huang X-F, Han M, Deng C (2008) The effects of
antipsychotics on the density of cannabinoid receptors in the dorsal vagal
complex of rats: implications for olanzapine-induced weight gain.
Int J Neuropsychopharmacol 11: 827–835.
36. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors.
Pharmacol Ther 74: 129–180.
37. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005)
Identification and Functional Characterization of Brainstem Cannabinoid CB2
Receptors. Science 310: 329–332.
38. Meeker RB, Myers RD (1980) GABA and glutamate: Possible metabolic
intermediaries involved in the hypothalamic regulation of food intake. Brain
Res Bull 5: 253–259.
39. Vong L, Ye C, Yang Z, Choi B, Chua S, et al. (2011) Leptin Action on
GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to
POMC Neurons. Neuron 71: 142–154.
40. Meister B (2007) Neurotransmitters in key neurons of the hypothalamus that
regulate feeding behavior and body weight. Physiol Behav 92: 263–271.
41. Akbarian S, Huang H-S (2006) Molecular and cellular mechanisms of altered
GAD1/GAD67 expression in schizophrenia and related disorders. Brain
Research Reviews 52: 293–304.
42. Kaufman DL, Houser CR, Tobin AJ (1991) Two Forms of the c-Aminobutyric
Acid Synthetic Enzyme Glutamate Decarboxylase Have Distinct Intraneuronal
Distributions and Cofactor Interactions. J Neurochem 56: 720–723.
43. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR (1994)
Comparative localization of two forms of glutamic acid decarboxylase and
their mRNAs in rat brain supports the concept of functional differences
between the forms. J Neurosci 14: 1834–1855.
44. Martin DL, Rimvall K (1993) Regulation of c-Aminobutyric Acid Synthesis in
the Brain. J Neurochem 60: 395–407.
45. Feldblum S, Erlander MG, Tobin AJ (1993) Different distributions of GAD65
and GAD67 mRNAS suggest that the two glutamate decarboxylases play
distinctive functional roles. J Neurosci Res 34: 689–706.
46. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG (2000) Central
nervous system control of food intake. Nature 404: 661–671.
47. Bronstein DM, Schafer MKH, Watson SJ, Akil H (1992) Evidence that [beta]-
endorphin is synthesized in cells in the nucleus tractus solitarius: detection of
POMC mRNA. Brain Res 587: 269–275.
48. Wai S, Kindler P, Lam E, Zhang A, Yew D (2004) Distribution of
neuropeptide Y-immunoreactive neurons in the human brainstem, cerebellum,
and cortex during development. Cell Mol Neurobiol 24: 667–684.
49. Wu Q, Palmiter RD (2011) GABAergic signaling by AgRP neurons prevents
anorexia via a melanocortin-independent mechanism. Eur J Pharmacol 660:
21–27.
50. Beck B (2006) Neuropeptide Y in normal eating and in genetic and dietary-
induced obesity. Philosophical Transactions of the Royal Society B: Biological
Sciences 361: 1159–1185.
51. Heilig M, Murison R (1987) Intracerebroventricular neuropeptide Y
suppresses open field and home cage activity in the rat. Regul Pept 19:
221–231.
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